The global qPCR instruments market size accounted for USD 6.8 billion in 2025 and is predicted to increase from USD 7.41 billion in 2026 to approximately USD 15.95 billion by 2035, expanding at a CAGR of 8.9% from 2026 to 2035. The growing infectious diseases, expanding personalized medicines, technological advancements, R&D activities, and government initiatives are promoting the market growth.
rn
qPCR Instruments: The Market Highlights
rn
The qPCR instruments are the laboratory devices used for amplification and measurement of DNA in real-time. They are being used for the detection of infectious diseases, cancer, and genetic disorders, as well as the detection of pathogens, pollutants, and microbial contaminants in food, water, and soil. They are also used in gene expression analysis, vaccine development, and drug discovery and development.
rn
qPCR Instruments Market Outlook: Trends and Future Opportunities
rn
The growth in infectious disease testing is increasing the demand for qPCR instruments.
rn
- rn
- Expanding R&D activities are increasing the use of qPCR instruments for biomarker discovery, personalized medicine development, gene expression studies, etc.
- rn
- Rise in the food safety and environmental monitoring is also increasing their adoption rates.
- rn
- Growing advancements in point-of-care testing are also increasing the development of portable and miniaturized qPCR devices.
- rn
- Increasing technological advancements are driving the development of smart qPCR devices with automation, enhancing speed and data management.
- rn
rn
!["Estimated]("../insightimg/estimated-us-cancer-cases.webp" "\"Estimated")
rn
The graph represents the estimated cancer cases in the U.S. for the year 2026. It indicates that there will be a rise in cancer deaths and new cases, which will drive the demand for advanced diagnostic solutions. This, in turn, will increase the adoption of qPCR instruments for early and accurate cancer detection, R&D applications, and clinical trials, which will ultimately promote the market growth.
rn
Market Segmentation Overview
rn
- rn
- By product type, the instruments segment accounted for the highest revenue share of 42% of the market in 2025, as they are essential for qPCR testing. Their long life span and durability also increased their adoption rates. The presence of advanced features like automation, high throughput, and multiplexing also increased their use for various applications.
- rn
- By detection method type, the TaqMan probes segment held a major revenue share of 45% of the qPCR instruments market in 2025 and is expected to show the highest growth with a CAGR of 9.5% during the predicted time, due to their high specificity and sensitivity. Their real-time monitoring and reproducibility also increased their demand. The multiplexing capabilities and expanding clinical applications also increased their use.
- rn
- By throughput type, the medium throughput segment contributed the biggest revenue share of 37% of the qPCR instruments market in 2025, driven by their balanced capacity and affordability. They were also considered ideal for clinical testing and research labs with moderate load samples. Their flexibility also increased their use across research institutes and hospital labs.
- rn
- By application type, the clinical diagnostics segment held the largest revenue share of 48% of the qPCR instruments market in 2025 and is expected to show the highest growth rate with a CAGR of 9.6% during the upcoming years, due to high demand for infectious disease detection. Their rapid and accurate results also increased their adoption rates across hospitals and labs. Growth in government screening programs and demand for personalized medicine has also increased their use.
- rn
- By end user, the hospitals & diagnostic centers segment led the qPCR instruments market with 40% in 2025, as they are considered the primary site for disease testing. The high patient volume and government support also increased the adoption of qPCR instruments. The presence of skilled personnel and focus on quality care also increased their acceptance rates.
- rn
rn
Regional Analysis
rn
North America dominated the qPCR instruments market with 38% in 2025, due to the robust healthcare infrastructure, industries, and research institutes. This increased the use of qPCR instruments for early disease detection and R&D activities, where the government funding accelerated their adoption rates. Technological advancements have also increased their innovations and use.
rn
Asia Pacific held 24% share of the qPCR instruments market in 2025 and is expected to expand rapidly with a CAGR of 10.5% during the forecast period, due to expanding healthcare infrastructure and pharmaceutical and biotechnology industries. This is increasing the adoption of qPCR instruments for accurate disease detection and R&D purposes. Growing government support and health awareness are also contributing to the market growth.
rn
The Market Movers: Top qPCR Instrument Companies
rn
Thermo Fisher Scientific held the position of the market leader with its Applied Biosystems brand and QantStudio line, where Bio-Rad Laboratories was its competitor, driven by the high adoption of CFX Opus and CFX Opus Dx. Roche Diagnostics also sustained its position with its LightCycler series, where Danaher contributed to the market growth with the launch of automated molecular diagnostics and the GeneXpert system.
rn
Segments Covered in the Report
rn
By Product Type
rn
- rn
- Instrumentsrn
- rn
- Benchtop qPCR Systems
- rn
- Portable/Compact qPCR Systems
- rn
rn
- rn
- Consumables & Reagentsrn
- rn
- Assays & Kitsrn
- rn
- Gene Expression Kits
- rn
- Pathogen Detection Kits
- rn
- SNP Genotyping Kits
- rn
rn
- rn
rn
- rn
- Master Mixes
- rn
- Plates & Tubes
- rn
- Softwarern
- rn
- Data Analysis Software
- rn
- Cloud-based Platforms
- rn
rn
- rn
rn
By Detection Method
rn
- rn
- SYBR Green
- rn
- TaqMan Probes
- rn
- Molecular Beacons
- rn
- Others (Scorpions, FRET Probes)
- rn
rn
By Throughput
rn
- rn
- Low Throughput
- rn
- Medium Throughput
- rn
- High Throughput
- rn
rn
By Application
rn
- rn
- Clinical Diagnosticsrn
- rn
- Infectious Diseases
- rn
- Oncology
- rn
- Genetic Testing
- rn
rn
- rn
- Research Applicationsrn
- rn
- Gene Expression Analysis
- rn
- Genomics & Proteomics
- rn
rn
- rn
- Forensic Testing
- rn
- Food & Environmental Testing
- rn
rn
By End User
rn
- rn
- Hospitals & Diagnostic Centers
- rn
- Academic & Research Institutes
- rn
- Pharmaceutical & Biotechnology Companies
- rn
- Contract Research Organizations (CROs)
- rn
rn
By Region
rn
- rn
- North Americarn
- rn
- U.S.
- rn
- Canada
- rn
- Mexico
- rn
- Rest of North America
- rn
rn
- rn
- Latin Americarn
- rn
- Brazil
- rn
- Argentina
- rn
- Rest of Latin America
- rn
rn
- rn
- Europe rn
- rn
- Western Europe rn
- rn
- Germany
- rn
- Italy
- rn
- France
- rn
- Netherlands
- rn
- Spain
- rn
- Portugal
- rn
- Belgium
- rn
- Ireland
- rn
- UK
- rn
- Iceland
- rn
- Switzerland
- rn
- Poland
- rn
- Rest of Western Europe
- rn
rn
- rn
- Eastern Europe rn
- rn
- Austria
- rn
- Russia & Belarus
- rn
- Türkiye
- rn
- Albania
- rn
- Rest of Eastern Europe
- rn
rn
- rn
rn
- rn
- Asia Pacificrn
- rn
- China
- rn
- Taiwan
- rn
- India
- rn
- Japan
- rn
- Australia and New Zealand
- rn
- ASEAN Countries (Singapore, Malaysia)
- rn
- South Korea
- rn
- Rest of APAC
- rn
rn
- rn
- MEA rn
- rn
- GCC Countriesrn
- rn
- Saudi Arabia
- rn
- United Arab Emirates (UAE)
- rn
- Qatar
- rn
- Kuwait
- rn
- Oman
- rn
- Bahrain
- rn
rn
- rn
- South Africa
- rn
- Egypt
- rn
- Rest of MEA
- rn
rn
- rn
